Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines

Related articles

1. 10-Year Analysis of the Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Disease

   This article has 5 authors:

   1. Galina L. Ignatova
   2. Sergey N. Avdeev
   3. Vladimir N. Antonov
   4. Elena V. Blinova
   5. Mikhail V. Osikov

2. Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value

   This article has 9 authors:

   1. Katherine Hicks
   2. Ziyi Xiao
   3. Kelly Fust
   4. Michele Kohli
   5. Kyle Paret
   6. Weijie Zhang
   7. Maria de Pilar Martin Matos
   8. Keya Joshi
   9. Parinaz Ghaswalla

3. Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for SARS-CoV-2 vaccines in 2024 in Austria

   This article has 4 authors:

   1. Uwe Riedmann
   2. Martin Sprenger
   3. John PA Ioannidis
   4. Stefan Pilz